Page last updated: 2024-10-31

nafamostat and Neutropenia

nafamostat has been researched along with Neutropenia in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Uwagawa, T1
Sakamoto, T1
Yasuda, J1
Shiozaki, H1
Furukawa, K1
Onda, S1
Gocho, T1
Shiba, H1
Yanaga, K1

Trials

1 trial available for nafamostat and Neutropenia

ArticleYear
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
    Pancreas, 2021, 03-01, Volume: 50, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined

2021